Keyphrases
Confidence Interval
100%
Type 2 Diabetes Mellitus (T2DM)
100%
Systematic Meta-analysis
100%
Meta-analysis
100%
Type 2 Diabetic Patients
100%
Randomized Phase II Trial
100%
Tirzepatide
100%
Hemoglobin A1c (HbA1c)
50%
Fasting Plasma Glucose
33%
Randomized Controlled Trial
16%
Placebo
16%
Therapeutic Potential
16%
HbA1c Levels
16%
Safety Profile
16%
Uncontrolled Type 2 Diabetes
16%
Pooled Analysis
16%
A1 Receptor
16%
Glycemic Control
16%
Glycated Hemoglobin
16%
Glucose-lowering Drugs
16%
Glucagon-like
16%
Hypoglycemia
16%
Serious Adverse Events
16%
Receptor Agonist
16%
Acceptable Safety
16%
Glucose-dependent Insulinotropic Polypeptide
16%
GLP-1 Receptor Agonist
16%
Therapy Discontinuation
16%
Glycemic Efficacy
16%
Pharmacology, Toxicology and Pharmaceutical Science
Non Insulin Dependent Diabetes Mellitus
100%
Tirzepatide
100%
Hemoglobin A1c
66%
Glucagon Like Peptide 1 Receptor Agonist
33%
Placebo
16%
Randomized Controlled Trial
16%
Adverse Event
16%
Hypoglycemia
16%
Glycosylated Hemoglobin
16%
Gastric Inhibitory Polypeptide
16%